| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Focus on Molecular Imaging |
David Geffen School of Medicine at UCLA
Los Angeles, California
Correspondence: For correspondence or reprints contact: Anna M. Wu, Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095-1770. E-mail: awu{at}mednet.ucla.edu
ABSTRACT
The completion of the human genome, coupled with parallel major research efforts in proteomics and systems biology, has led to a flood of information on the roles of individual genes and proteins in normal physiologic processes and their disruptions in disease. In practical terms, this information has opened the door to increasingly targeted therapies as specific molecular markers are identified and validated. The ongoing transition from empiric to molecular medicine has engendered a need for corresponding molecular diagnostics, including noninvasive molecular imaging. Convergence of knowledge regarding key biomarkers that define normal biologic processes and disease with protein and imaging technology makes this an opportune time to revisit the combination of antibodies and PET, or immuno-PET.
Key Words: molecular imaging • PET • radioimmunoimaging • antibodies • biomarker imaging • immunoPET
Antibodies offer the promise of highly selective binding and recognition of molecular targets and have propelled the identification and analysis of specific proteins in research and in vitro diagnostic laboratories. However, the development of antibodies as clinical imaging agents has had a checkered history, with a handful of antibody tracers for nuclear medicine imaging gaining approval in the 1990s (satumomab pendetide [Oncoscint; Cytogen Corp.], capromab pendetide [Prostascint; Cytogen Corp.], and arcitumomab [CEA-Scan; Immunomedics]). As a group, antibody-based imaging agents have yet to make a significant impact in the clinical or commercial setting (1).
ANTIBODIES—EXPANDING APPLICATIONS IN IMAGING
Several recent developments are contributing to renewed interest in antibodies as molecular imaging agents (2). As a class, antibodies offer unmatched utility in their ability to recognize essentially any target of interest. In contrast, small molecules and peptides often require the presence of an active site, pocket, or groove for high-affinity interaction. One potential limitation of antibody-based molecular imaging is that the approach is restricted to the assessment of cell surface markers; intracellular targets are not accessible. Nonetheless, the surface-expression patterns of receptors, ligands, adhesion molecules, proteases, and differentiation and activation markers provide a rich source of information on the state of a cell; these proteins represent potential targets for antibody-based molecular imaging (Fig. 1).
|
) (Humira; Abbott Laboratories), among others, attests to the ability of antibodies to localize and engage or block critical biologic targets in patients. Although antibodies in general are incapable of crossing the blood–brain barrier, antibody therapeutics are finding clinical applications in neurologic diseases such as multiple sclerosis and Alzheimer disease, and strategies for direct delivery to the brain are under development (3). The list of antibody therapeutics moving through phase II/III studies continues to expand, and most major pharmaceutical companies have active antibody development programs. Given the increasing acceptance of antibodies as an effective class of molecular therapeutics, it makes sense to revisit antibodies as potential molecular imaging agents as well. Broad progress in biomarker identification and validation, coupled with advances on both the antibody and antimatter sides, makes immuno-PET increasingly practical and achievable. SOURCES OF ANTIBODIES FOR MOLECULAR IMAGING
Current antibody technologies provide robust methods for isolation of novel antibodies specific for any target of interest. First-generation antibody imaging agents were derived from immunogenic mouse monoclonal antibodies. Since then, humanization of murine antibodies for clinical use has become routine, and fully human antibodies can be produced by immunization of mice genetically engineered to carry germline human immunoglobulin genes. Display technologies (phage display, yeast display, ribosome display, etc.) provide an alternative approach for identifying human antibodies with desired binding properties. Recent regulatory approvals of adalimumab and panitumumab (Vectibix; Amgen) validate phage display and transgenic mice as sources of novel human antibodies for clinical use.
Beyond antibodies, interest in alternative small-protein scaffolds as a source of binding molecules for molecular targeting is rapidly expanding (4). Recent examples include single-domain antibodies (of human, camellid, or shark origin), small proteins based on fibronectin domains, ankyrin repeats, or protein A domains (Affibodies; Affibody AB). Alternative scaffolds have been developed to provide binding domains with differing sizes and shapes, compared with the large, relatively flat binding surfaces of antibodies. Protein domains have been selected for ease of expression in microbial systems and high stability under physiologic and nonphysiologic conditions. Display technology facilitates rapid selection of binding agents with the desired specificity. For example, a monovalent affibody with high affinity for Her2 has been produced and demonstrates excellent in vivo targeting and imaging in tumor-bearing mice (5,6).
ENGINEERED ANTIBODY FRAGMENTS FOR OPTIMIZING PHARMACOKINETICS
Radiolabeled intact antibodies, with blood-clearance half-lives of days to weeks, are far from optimal for imaging purposes; circulating activity in the blood necessitates long delays between administration of the tracer and acquisition of the final image. Initially, enzymatic digestion of antibodies to yield Fab or F(ab')2 fragments provided a simple approach to reducing background, because fragments lacking the immunoglobulin fragment crystallizable (Fc) region are cleared much more rapidly from the blood. Arcitumomab represents an example of a carcinoembryonic antigen (CEA)–targeting Fab fragment that demonstrated utility in imaging metastatic colon cancer in patients.
The development of antibodies for molecular imaging has been promoted by the development of engineered fragments with pharmacokinetics optimized for imaging (Fig. 2). Reduction of the overall size of antibody-based fragments can result in accelerated blood clearance due to removal of the Fc region (which interacts with neonatal Fc receptors in vivo to prolong half-life) and by reduction of the molecular weight to a size below the threshhold for first-pass renal clearance (
60 kDa). Single-chain variable fragments (scFvs) provide a convenient building block for engineered antibody fragments that retain full binding specificity (e.g., diabodies, triabodies, and tetrabodies [dimers, trimers, and multimers of scFv] and tandem diabodies). Fusion of scFvs to additional antibody domains such as the CH3 domain to generate minibodies (scFv-CH3) and the closely related small immunoproteins and the larger scFv-Fc fusion proteins (7) is another example. These fragments typically retain the high affinity and specificity of the parental antibody but also exhibit a range of blood-clearance properties that are format-dependent (8).
|
20% injected dose/g) can be achieved in target tissues, resulting in excellent imaging, although optimal imaging times may be longer. High-affinity, monovalent Her2-specific affibodies demonstrated impressive targeting and retention in preclinical models (5), counter to the prevailing wisdom that bivalent molecules are necessary for optimal targeting and retention.
Clinical Potential
A high priority is translation of engineered antibody-based imaging agents to establish pharmacokinetics and targeting in patients, because prediction of clinical performance based on preclinical studies in rodents is challenging. Initial SPECT studies using 123I-labeled L19 (scFv)2 specific for fibronectin ED-B (a biomarker of neovascularization) showed that detection of tumor-associated angiogenesis in patients was feasible at 6 h after injection (11). A subsequent phase I/II clinical study similarly showed excellent targeting in 4 of 5 patients with head and neck squamous cell carcinoma (12). Planar and SPECT studies using the 123I-cT84.66 CEA-specific minibody in a presurgical study of patients with recurrent colorectal carcinoma demonstrated localization to 8 of 10 lesions larger than 1.0 cm (13).
Encouraging results from these and other proof-of-principle studies using engineered fragments labeled with single photon–emitting isotopes lay a strong foundation for the development of these reagents as immuno-PET tracers, given the higher sensitivity and resolution of PET scanners and the ability to quantitate activity—and thus expression levels—of molecular targets in vivo.
ANTIMATTER—PROGRESS WITH POSITRON-EMITTING RADIONUCLIDES
Matching Biologic and Physical Half-Lives
Marrying antibodies and positron-emitting radionuclides for PET applications requires an appropriate match between the biologic half-life of the protein and the physical half-life of the isotope. For example, it makes little sense to radiolabel an intact antibody (half-life [t1/2β] = 7–14 d) with 18F (t1/2 = 109 min); by the time optimal antibody targeting, distribution, and clearance are achieved in vivo, any potential signal will have decayed. Successful implementation of immuno-PET requires access to radionuclides with a longer half-life. For this reason, initial encouraging demonstrations of immuno-PET in the 1990s remained limited in their effect because of the lack of broad access to "exotic" PET radionuclides such as 124I and 64Cu. More recently, with the widespread adoption of PET using 18F-FDG, PET scanners have become ubiquitous in nuclear medicine departments, and attention has increasingly turned to the development of novel molecular tracers for use in PET.
Several PET radionuclides have been the focus of recent clinical and preclinical studies (Table 1). Ideally, alignment of the physical half-life of the radiolabel and biologic half-life of the tracer will lead to optimal imaging performance. In practical terms, combinations that may appear suboptimal (such as radiolabeling small, rapid-clearing fragments with 124I (9) or intact antibodies with 64Cu (14,15) or 86Y (16)) have nonetheless yielded highly informative images and data in preclinical studies.
|
) will have major effects on the amount of activity that needs to be administered and the radiation dose to the patient or health care providers. Positron range may affect resolution if the positron travels a significant distance before annihilation. Finally, commercial availability and cost of positron-emitting radionuclides are also significant issues that continue to shape (or impede) progress in the development of immuno-PET. PET radionuclides with half-lives on the order of days would be ideally suited for conjugation with intact antibodies for clinical imaging (Table 1), and recent efforts have gravitated toward 89Zr (78.4 h) and 124I (100.2 h). Recent examples of radiolabeling and preclinical evaluation of intact antibodies with 89Zr include labeling of ibritumomab tiuxetan (Zevalin; Cell Therapeutics Inc.) with 89Zr (18) and development of a 89Zr-Met–specific antibody (19). The clinical utility of 89Zr-labeled U36, a chimeric antibody specific for CD44v6, has been demonstrated in a series of 20 patients with head and neck cancer (20). All of the primary tumors and 72% of the lymph node metastases (confirmed by pathology) were detected in this clinical immuno-PET study. Improved commercial availability of 124I has also led to renewed interest in clinical evaluation. Immuno-PET imaging of 26 patients with renal masses after injection of 124I-cG250 (anticarbonic anhydrase-IX) resulted in successful detection of 15 of 16 clear-cell carcinomas (21). In these presurgical studies, the final immuno-PET scans were acquired 6–8 d after injection, just before surgery.
Antibody fragments offer practical advantages for immuno-PET applications, because they can reduce the interval between injection and imaging to hours instead of the days required for clearance of intact antibodies. PET radionuclides with short or intermediate half-lives (Table 1) have been used in combination with fragments, engineered and conventional, in a growing body of preclinical studies. Conventional F(ab')2 fragments derived from trastuzumab and radiolabeled with 68Ga have been used to evaluate response to treatment by in vivo PET of Her2 expression after administration of 17-AAG, a drug that accelerates Her2 degradation (22).
Immuno-PET detection of Her2 expression in tumor xenografts in mice has also been achieved using 124I-C6.5 diabodies (10), 64Cu-labeled minibodies, and scFv-Fc fragments derived from trastuzumab (23). 76Br-labeled L19 small-immunoprotein fragments were successfully used to image tumor neovasculature in murine models, although normal-tissue uptake was observed in the ovaries and uterus, and partial debromination was observed (24). Pretargeted imaging using a multivalent, recombinant bispecific antibody has been transitioned to PET detection by using a 124I-radiolabeled hapten peptide as the tracer (25). One of the most promising developments, with implications for clinical translation, is the demonstration of rapid 18F labeling and imaging of colon carcinoma xenografts using an anti-CEA diabody (26). The antigen-positive tumor was readily detected by small-animal PET imaging at time points from 1 to 6 h after injection.
Finally, realization of protein-based PET tracers will require continued innovations in conjugation and radiolabeling methods. As various cell surface proteins are proposed as candidates for antibody imaging, an important first question is whether the antibody or antigen complex is internalized. If not, then simple radiohalogenation methods can be used to generate a suitable tracer, and the radioactive signal will persist at the target site. Figure 3 shows that minibodies that recognize the noninternalizing targets CEA and prostate stem cell antigen (glycosylphosphatidyl-inositol–linked membrane proteins) or CD20 (integral membrane protein) provide excellent small-animal PET images after standard radioiodination with 124I. An added advantage is that a nonlocalized tracer is cleared to the liver, kidney, or spleen and catabolized with rapid clearance of the radioactive metabolites. As a result, normal-tissue background is low. However, many cell surface targets of interest are internalized, necessitating the use of a residualizing radiolabel. Stabilized iodination protocols (10), or radiometal chelates, are required. Continued development of improved bifunctional chelates for positron-emitting radionuclides continues to be of critical importance.
|
An impressive range of positron-emitting radionuclides (Table 1) and a broad spectrum of molecular targets are under active investigation in immuno-PET studies. Progress is accelerating because of the identification of key cell surface markers as potential molecular imaging biomarkers, broad antibody technology that facilitates rapid isolation and reformatting into immuno-PET tracers, and advances in production and use of additional PET radionuclides for labeling biomolecules. In oncologic applications, availability of PET tracers for assessment of cell surface biomarkers can play an important role at many points along the cancer-care continuum: for tumor detection and identification (i.e., tissue of origin); at diagnosis, staging, and restaging; for treatment selection and monitoring; and during follow-up. Immuno-PET can potentially be used to evaluate target expression and accessibility before treatment with an antibody therapeutic. Quantitation of tissue uptake and dosimetry for radioimmunotherapy is an area to which immuno-PET can contribute significantly, because of the availability of matched imaging or therapeutic radioisotope pairs, such as 64Cu/67Cu, 86Y/90Y, and 124I/131I. Challenges remain, because many targets that are efficacious in therapeutic applications (such as epidermal growth factor receptor) will not be imageable because of normal-tissue expression. Radionuclide availability and continued development of radiochemistry and coordination chemistry are areas that need to be addressed if broad clinical use is envisioned. Nonetheless, immuno-PET will provide a means to "fingerprint" the cell surface and tissues in vivo, and translation to the clinical setting will add a new dimension to our understanding of disease and its treatment.
FOOTNOTES
COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
References
vβ3. Cancer Res. 2006;66:9673–9681.Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  P. K.E. Borjesson, Y. W.S. Jauw, R. de Bree, J. C. Roos, J. A. Castelijns, C. R. Leemans, G. A.M.S. van Dongen, and R. Boellaard Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients J. Nucl. Med., November 1, 2009; 50(11): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nimmagadda, M. Pullambhatla, and M. G. Pomper Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT J. Nucl. Med., July 1, 2009; 50(7): 1124 - 1130. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
